Login Register Cart 0
Generic placeholder image

Current Psychiatry Research and Reviews

Editor-in-Chief

ISSN (Print): 2666-0822
ISSN (Online): 2666-0830

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Inflammation Biomarkers in Psychiatry

Author(s): Alper Evrensel* and Nevzat Tarhan

Volume 16, Issue 2, 2020

Page: [78 - 85] Pages: 8

DOI: 10.2174/2666082216999200625115701

Price: $65

Abstract

Introduction: There has long been a need for diagnostic, theragnostic, and prognostic biomarkers for psychiatric disorders. Biomarkers help in reducing ambiguity and arbitrariness and increase objectivity. In this context, many candidates for hormonal, immunological, serological, and neuroimaging markers have been proposed, but none of these marker candidates alone nor a biomarker panel has been approved for any disease. The fact that almost all psychiatric disorders are heterogeneous makes this process challenging. However, strong biomarker candidates have been identified, especially in light of the large number of clinical and preclinical studies conducted within the last five years.

Objective: The aim of this article was to compile and discuss the current information on immune biomarkers in major psychiatric disorders, such as schizophrenia, depression, bipolar disorder, and anxiety disorders.

Methods: In this study, respected scientific databases were searched using key terms related to the subject, and the related literature was examined in detail.

Results: There are many relationships between psychiatric disorders and immune system parameters. Evidence also suggests that neuroinflammation is involved in the etiopathogenesis of psychiatric disorders. Markers, such as proinflammatory cytokines, tumor necrosis factor alpha, and C-reactive protein have been associated with psychiatric disorders in numerous studies.

Conclusions: The neuroinflammation hypothesis has an important place in the etiopathogenesis of psychiatric disorders. Uncertainty remains as to whether neuroinflammation is a cause or consequence of psychiatric disorders. Some researchers have indicated that intestinal microbiota composition disorders and dysbiosis are sources of neuroinflammation. Immune marker studies are of great importance in terms of eliminating this uncertainty and overcoming diagnostic and treatment difficulties in the clinic. In this review, biomarker studies on psychiatric disorders were examined from the viewpoint of the immune system and discussed in light of the current studies.

Keywords: Biomarkers, neuroinflammation, immune system, psychiatry, diagnostic, theragnostic, prognostic.

« Previous Next »
Graphical Abstract

[1]
Yirmiya R, Rimmerman N, Reshef R. Depression as a microglial disease. Trends Neurosci 2015; 38(10): 637-58.
[http://dx.doi.org/10.1016/j.tins.2015.08.001] [PMID: 26442697]
[2]
Muldoon LL, Alvarez JI, Begley DJ, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab 2013; 33(1): 13-21.
[http://dx.doi.org/10.1038/jcbfm.2012.153] [PMID: 23072749]
[3]
Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523(7560): 337-41.
[http://dx.doi.org/10.1038/nature14432] [PMID: 26030524]
[4]
Beumer W, Gibney SM, Drexhage RC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol 2012; 92(5): 959-75.
[http://dx.doi.org/10.1189/jlb.0212100] [PMID: 22875882]
[5]
Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 2010; 12(6): 638-46.
[http://dx.doi.org/10.1111/j.1399-5618.2010.00853.x] [PMID: 20868462]
[6]
Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3): 89-95.
[http://dx.doi.org/10.1067/mcp.2001.113989] [PMID: 11240971]
[7]
Schneider B, Prvulovic D. Novel biomarkers in major depression. Curr Opin Psychiatry 2013; 26(1): 47-53.
[http://dx.doi.org/10.1097/YCO.0b013e32835a5947] [PMID: 23154643]
[8]
Gururajan A, Clarke G, Dinan TG, Cryan JF. Molecular biomarkers of depression. Neurosci Biobehav Rev 2016; 64: 101-33.
[http://dx.doi.org/10.1016/j.neubiorev.2016.02.011] [PMID: 26906761]
[9]
Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51(6): 1173-82.
[http://dx.doi.org/10.1037/0022-3514.51.6.1173] [PMID: 3806354]
[10]
Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002; 59(10): 877-83.
[http://dx.doi.org/10.1001/archpsyc.59.10.877] [PMID: 12365874]
[11]
Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011; 36(12): 2375-94.
[http://dx.doi.org/10.1038/npp.2011.151] [PMID: 21814182]
[12]
Nasrallah HA. Biomarkers in neuropsychiatric disorders: translating research to clinical applications. Biomarkers in Neuropsychiatry 2019; 1100001
[http://dx.doi.org/10.1016/j.bionps.2019.100001]
[13]
Sigitova E, Fišar Z, Hroudová J, Cikánková T, Raboch J. Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci 2017; 71(2): 77-103.
[http://dx.doi.org/10.1111/pcn.12476] [PMID: 27800654]
[14]
Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. Theranostic biomarkers for schizophrenia. Int J Mol Sci 2017; 18(4): 733.
[http://dx.doi.org/10.3390/ijms18040733] [PMID: 28358316]
[15]
Kim YK, Amidfar M, Won E. A review on inflammatory cytokine-induced alterations of the brain as potential neural biomarkers in post-traumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2019; 91: 103-12.
[http://dx.doi.org/10.1016/j.pnpbp.2018.06.008] [PMID: 29932946]
[16]
Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65(9): 732-41.
[http://dx.doi.org/10.1016/j.biopsych.2008.11.029] [PMID: 19150053]
[17]
Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 2012; 83(5): 495-502.
[http://dx.doi.org/10.1136/jnnp-2011-301779] [PMID: 22423117]
[18]
Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013; 246: 199-229.
[http://dx.doi.org/10.1016/j.neuroscience.2013.04.060] [PMID: 23644052]
[19]
Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011; 25(2): 181-213.
[http://dx.doi.org/10.1016/j.bbi.2010.10.015] [PMID: 20970492]
[20]
Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012; 37(1): 137-62.
[http://dx.doi.org/10.1038/npp.2011.205] [PMID: 21918508]
[21]
Evrensel A, Ünsalver BÖ, Ceylan ME. Immune-kynurenine pathways and the gut microbiota-brain axis in anxiety disorders. Adv Exp Med Biol 2020; 1191: 155-67.
[http://dx.doi.org/10.1007/978-981-32-9705-0_10] [PMID: 32002928]
[22]
Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci USA 2010; 107(6): 2669-74.
[http://dx.doi.org/10.1073/pnas.0910658107] [PMID: 20133768]
[23]
Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302(5651): 1760-5.
[http://dx.doi.org/10.1126/science.1088417] [PMID: 14615545]
[24]
Kaneko N, Kudo K, Mabuchi T, et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006; 31(12): 2619-26.
[http://dx.doi.org/10.1038/sj.npp.1301137] [PMID: 16823390]
[25]
Iosif RE, Ekdahl CT, Ahlenius H, et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 2006; 26(38): 9703-12.
[http://dx.doi.org/10.1523/JNEUROSCI.2723-06.2006] [PMID: 16988041]
[26]
Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007; 21(1): 9-19.
[http://dx.doi.org/10.1016/j.bbi.2006.08.009] [PMID: 17070667]
[27]
Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446-57.
[http://dx.doi.org/10.1016/j.biopsych.2009.09.033] [PMID: 20015486]
[28]
Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 2013; 150(3): 736-44.
[http://dx.doi.org/10.1016/j.jad.2013.06.004] [PMID: 23870425]
[29]
Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 2015; 25(10): 1532-43.
[http://dx.doi.org/10.1016/j.euroneuro.2015.06.007] [PMID: 26169573]
[30]
Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011; 36(12): 2452-9.
[http://dx.doi.org/10.1038/npp.2011.132] [PMID: 21796103]
[31]
Hestad KA, Tønseth S, Støen CD, Ueland T, Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003; 19(4): 183-8.
[http://dx.doi.org/10.1097/00124509-200312000-00002] [PMID: 14657769]
[32]
Janelidze S, Mattei D, Westrin Å, Träskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011; 25(2): 335-9.
[http://dx.doi.org/10.1016/j.bbi.2010.10.010] [PMID: 20951793]
[33]
Young JJ, Silber T, Bruno D, Galatzer-Levy IR, Pomara N, Marmar CR. Is there progress? An overview of selecting biomarker candidates for major depressive disorder. Front Psychiatry 2016; 7: 72.
[http://dx.doi.org/10.3389/fpsyt.2016.00072] [PMID: 27199779]
[34]
Karlović D, Serretti A, Vrkić N, Martinac M, Marčinko D. Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res 2012; 198(1): 74-80.
[http://dx.doi.org/10.1016/j.psychres.2011.12.007] [PMID: 22386567]
[35]
Evrensel A, Ceylan ME. The gut-brain axis: the missing link in depression. Clin Psychopharmacol Neurosci 2015; 13(3): 239-44.
[http://dx.doi.org/10.9758/cpn.2015.13.3.239] [PMID: 26598580]
[36]
Söderlund J, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci 2011; 36(2): 114-8.
[http://dx.doi.org/10.1503/jpn.100080] [PMID: 21138659]
[37]
Çakır U, Tuman TC, Yıldırım O. Increased neutrophil/lymphoctye ratio in patients with bipolar disorder: a preliminary study. Psychiatr Danub 2015; 27(2): 180-4.
[PMID: 26057314]
[38]
Chrysanthou-Piterou M, Havaki S, Alevizos V, Papadimitriou GN, Issidorides MR. Chromatin ultrastructural abnormalities in leukocytes, as peripheral markers of bipolar patients. Ultrastruct Pathol 2009; 33(5): 197-208.
[http://dx.doi.org/10.3109/01913120903288579] [PMID: 19895292]
[39]
Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord 2010; 126(3): 458-62.
[http://dx.doi.org/10.1016/j.jad.2010.04.027] [PMID: 20537397]
[40]
Barbosa IG, Huguet RB, Mendonça VA, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011; 261(2): 139-43.
[http://dx.doi.org/10.1007/s00406-010-0116-z] [PMID: 20446090]
[41]
Panizzutti B, Gubert C, Schuh AL, et al. Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder:a accelerated aging biomarker? J Affect Disord 2015; 182: 64-9.
[http://dx.doi.org/10.1016/j.jad.2014.12.010] [PMID: 25973785]
[42]
Barbosa IG, Rocha NP, de Miranda AS, et al. Increased levels of adipokines in bipolar disorder. J Psychiatr Res 2012; 46(3): 389-93.
[http://dx.doi.org/10.1016/j.jpsychires.2011.11.010] [PMID: 22137759]
[43]
Remlinger-Molenda A, Wojciak P, Michalak M, Karczewski J, Rybakowski JK. Selected cytokine profiles during remission in bipolar patients. Neuropsychobiology 2012; 66(3): 193-8.
[http://dx.doi.org/10.1159/000339949] [PMID: 22948566]
[44]
Hope S, Dieset I, Agartz I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011; 45(12): 1608-16.
[http://dx.doi.org/10.1016/j.jpsychires.2011.08.003] [PMID: 21889167]
[45]
Chou YH, Hsieh WC, Chen LC, Lirng JF, Wang SJ. Association between the serotonin transporter and cytokines: Implications for the pathophysiology of bipolar disorder. J Affect Disord 2016; 191: 29-35.
[http://dx.doi.org/10.1016/j.jad.2015.10.056] [PMID: 26630394]
[46]
Ortiz-Domínguez A, Hernández ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007; 9(6): 596-602.
[http://dx.doi.org/10.1111/j.1399-5618.2007.00493.x] [PMID: 17845274]
[47]
O’Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90(2-3): 263-7.
[http://dx.doi.org/10.1016/j.jad.2005.11.015] [PMID: 16410025]
[48]
Mota R, Gazal M, Acosta BA, et al. Interleukin-1β is associated with depressive episode in major depression but not in bipolar disorder. J Psychiatr Res 2013; 47(12): 2011-4.
[http://dx.doi.org/10.1016/j.jpsychires.2013.08.020] [PMID: 24074516]
[49]
Monfrim X, Gazal M, De Leon PB, et al. Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1β? Bipolar Disord 2014; 16(7): 741-7.
[http://dx.doi.org/10.1111/bdi.12214] [PMID: 24862833]
[50]
Guloksuz S, Altinbas K, Aktas Cetin E, et al. Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J Affect Disord 2012; 143(1-3): 148-52.
[http://dx.doi.org/10.1016/j.jad.2012.04.044] [PMID: 22749155]
[51]
Kim YK, Myint AM, Lee BH, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 2004; 129(3): 267-72.
[http://dx.doi.org/10.1016/j.psychres.2004.08.005] [PMID: 15661320]
[52]
Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104(1-3): 91-5.
[http://dx.doi.org/10.1016/j.jad.2007.02.018] [PMID: 17434599]
[53]
Li H, Hong W, Zhang C, et al. IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J Affect Disord 2015; 174: 361-6.
[http://dx.doi.org/10.1016/j.jad.2014.12.033] [PMID: 25545602]
[54]
Avramopoulos D, Pearce BD, McGrath J, et al. Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. PLoS One 2015; 10(3)e0116696
[http://dx.doi.org/10.1371/journal.pone.0116696] [PMID: 25781172]
[55]
Wium-Andersen MK, Ørsted DD, Nordestgaard BG. Elevated C-reactive protein and late-onset bipolar disorder in 78 809 individuals from the general population. Br J Psychiatry 2016; 208(2): 138-45.
[http://dx.doi.org/10.1192/bjp.bp.114.150870] [PMID: 26250741]
[56]
Chung KH, Huang SH, Wu JY, Chen PH, Hsu JL, Tsai SY. The link between high-sensitivity C-reactive protein and orbitofrontal cortex in euthymic bipolar disorder. Neuropsychobiology 2013; 68(3): 168-73.
[http://dx.doi.org/10.1159/000353613] [PMID: 24051690]
[57]
Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 2013; 150(2): 456-9.
[http://dx.doi.org/10.1016/j.jad.2013.04.039] [PMID: 23684514]
[58]
Bai YM, Su TP, Tsai SJ, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord 2014; 166: 187-92.
[http://dx.doi.org/10.1016/j.jad.2014.05.009] [PMID: 25012430]
[59]
Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res 2015; 228(3): 386-92.
[http://dx.doi.org/10.1016/j.psychres.2015.05.078] [PMID: 26160203]
[60]
Cunha AB, Andreazza AC, Gomes FA, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2008; 258(5): 300-4.
[http://dx.doi.org/10.1007/s00406-007-0797-0] [PMID: 18297417]
[61]
Maes M, Delange J, Ranjan R, et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997; 66(1): 1-11.
[http://dx.doi.org/10.1016/S0165-1781(96)02915-0] [PMID: 9061799]
[62]
Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23(2): 87-94.
[http://dx.doi.org/10.1002/hup.912] [PMID: 18172906]
[63]
Kargar M, Yousefi A, Mojtahedzadeh M, et al. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Med Wkly 2014; 144w13880
[http://dx.doi.org/10.4414/smw.2014.13880] [PMID: 24554598]
[64]
Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167(3): 261-80.
[http://dx.doi.org/10.1176/appi.ajp.2009.09030361] [PMID: 20123911]
[65]
Benros ME, Pedersen MG, Rasmussen H, Eaton WW, Nordentoft M, Mortensen PB. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am J Psychiatry 2014; 171(2): 218-26.
[http://dx.doi.org/10.1176/appi.ajp.2013.13010086] [PMID: 24129899]
[66]
Nielsen PR, Benros ME, Mortensen PB. Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of Danish national registers. Schizophr Bull 2014; 40(6): 1526-32.
[http://dx.doi.org/10.1093/schbul/sbt200] [PMID: 24379444]
[67]
Gao L, Li Z, Chang S, Wang J. Association of interleukin-10 polymorphisms with schizophrenia: a meta-analysis. PLoS One 2014; 9(3)e90407
[http://dx.doi.org/10.1371/journal.pone.0090407] [PMID: 24603720]
[68]
Hudson ZD, Miller BJ. Meta-analysis of cytokine and chemokine genes in schizophrenia. Clin Schizophr Relat Psychoses 2018; 12(3): 121-129B.
[http://dx.doi.org/10.3371/CSRP.HUMI.070516] [PMID: 27454212]
[69]
Qin H, Zhang L, Xu G, Pan X. Lack of association between TNFα rs1800629 polymorphism and schizophrenia risk: a meta-analysis. Psychiatry Res 2013; 209(3): 314-9.
[http://dx.doi.org/10.1016/j.psychres.2013.01.019] [PMID: 23453739]
[70]
Shibuya M, Watanabe Y, Nunokawa A, et al. Interleukin 1 beta gene and risk of schizophrenia: detailed case-control and family-based studies and an updated meta-analysis. Hum Psychopharmacol 2014; 29(1): 31-7.
[http://dx.doi.org/10.1002/hup.2365] [PMID: 24155145]
[71]
Xu M, He L. Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophr Res 2010; 120(1-3): 131-42.
[http://dx.doi.org/10.1016/j.schres.2010.02.1031] [PMID: 20347268]
[72]
Gaughran F, O’Neill E, Sham P, Daly RJ, Shanahan F. Soluble interleukin 2 receptor levels in families of people with schizophrenia. Schizophr Res 2002; 56(3): 235-9.
[http://dx.doi.org/10.1016/S0920-9964(01)00275-4] [PMID: 12072172]
[73]
Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM. Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatry Clin Neurosci 1993; 243(1): 7-10.
[http://dx.doi.org/10.1007/BF02191517] [PMID: 8399412]
[74]
Martínez-Gras I, García-Sánchez F, Guaza C, et al. Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Res 2012; 200(2-3): 1022-5.
[http://dx.doi.org/10.1016/j.psychres.2012.05.036] [PMID: 22766011]
[75]
Liu L, Jia F, Yuan G, et al. Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. Psychiatry Res 2010; 176(1): 1-7.
[http://dx.doi.org/10.1016/j.psychres.2008.10.024] [PMID: 20067853]
[76]
Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res 2006; 84(1): 180-2.
[http://dx.doi.org/10.1016/j.schres.2006.02.003] [PMID: 16530388]
[77]
Choi GB, Yim YS, Wong H, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Sci 2016; 351(6276): 933-9.
[http://dx.doi.org/10.1126/science.aad0314] [PMID: 26822608]
[78]
Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27(40): 10695-702.
[http://dx.doi.org/10.1523/JNEUROSCI.2178-07.2007] [PMID: 17913903]
[79]
Girard S, Tremblay L, Lepage M, Sébire G. IL-1 receptor antagonist protects against placental and neurodevelopmental defects induced by maternal inflammation. J Immunol 2010; 184(7): 3997-4005.
[http://dx.doi.org/10.4049/jimmunol.0903349] [PMID: 20181892]
[80]
Zhang J, Luo W, Huang P, Peng L, Huang Q. Maternal C-reactive protein and cytokine levels during pregnancy and the risk of selected neuropsychiatric disorders in offspring: a systematic review and meta-analysis. J Psychiatr Res 2018; 105: 86-94.
[http://dx.doi.org/10.1016/j.jpsychires.2018.09.002] [PMID: 30212728]
[81]
Cooper JD, Ozcan S, Gardner RM, et al. Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots. Transl Psychiatry 2017; 7(12): 1290.
[http://dx.doi.org/10.1038/s41398-017-0027-0] [PMID: 29249827]
[82]
Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014; 71(10): 1121-8.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.1332] [PMID: 25133871]
[83]
Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016; 21(12): 1696-709.
[http://dx.doi.org/10.1038/mp.2016.3] [PMID: 26903267]
[84]
Park S, Miller BJ. Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis. Schizophr Res 2019; 9964(19): 30106-9.
[85]
Mondelli V, Ciufolini S, Belvederi Murri M, et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr Bull 2015; 41(5): 1162-70.
[http://dx.doi.org/10.1093/schbul/sbv028] [PMID: 25829375]
[86]
Nettis MA, Pergola G, Kolliakou A, et al. Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis. Psychoneuroendocrinology 2019; 99: 145-53.
[http://dx.doi.org/10.1016/j.psyneuen.2018.09.005] [PMID: 30243054]
[87]
Vogelzangs N, Beekman AT, de Jonge P, Penninx BW. Anxiety disorders and inflammation in a large adult cohort. Transl Psychiatry 2013; 3e249
[http://dx.doi.org/10.1038/tp.2013.27] [PMID: 23612048]
[88]
Khandaker GM, Zammit S, Lewis G, Jones PB. Association between serum C-reactive protein and DSM-IV generalized anxiety disorder in adolescence: findings from the ALSPAC cohort. Neurobiol Stress 2016; 4: 55-61.
[http://dx.doi.org/10.1016/j.ynstr.2016.02.003] [PMID: 27830164]
[89]
Nayek S, Ghosh S. A comparative study of serum C-reactive protein in patients with generalised anxiety disorder and depression. Indian J Psychiatry 2017; 59: S217.
[90]
Tang Z, Ye G, Chen X, et al. Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder. J Affect Disord 2018; 225: 593-8.
[http://dx.doi.org/10.1016/j.jad.2017.08.082] [PMID: 28886500]
[91]
Copeland WE, Shanahan L, Worthman C, Angold A, Costello EJ. Generalized anxiety and C-reactive protein levels: a prospective, longitudinal analysis. Psychol Med 2012; 42(12): 2641-50.
[http://dx.doi.org/10.1017/S0033291712000554] [PMID: 22716910]
[92]
Zahm JL. Generalized anxiety disorder and inflammatory biomarkers in coronary heart disease: Sex-specific effects Diss Abstr Int. Sci Eng 2018; p. 78.
[93]
Yang CJ, Liu D, Xu ZS, Shi SX, Du YJ. The pro-inflammatory cytokines, salivary cortisol and alpha-amylase are associated with generalized anxiety disorder (GAD) in patients with asthma. Neurosci Lett 2017; 656: 15-21.
[http://dx.doi.org/10.1016/j.neulet.2017.07.021] [PMID: 28716529]
[94]
Hou R, Garner M, Holmes C, et al. Peripheral inflammatory cytokines and immune balance in generalised anxiety disorder: case-controlled study. Brain Behav Immun 2017; 62: 212-8.
[http://dx.doi.org/10.1016/j.bbi.2017.01.021] [PMID: 28161475]
[95]
Evrensel A, Ceylan ME. Fecal microbiota transplantation and its usage in neuropsychiatric disorders. Clin Psychopharmacol Neurosci 2016; 14(3): 231-7.
[http://dx.doi.org/10.9758/cpn.2016.14.3.231] [PMID: 27489376]
[96]
Evrensel A, Ünsalver BÖ, Ceylan ME. Neuroinflammation, gut-brain axis and depression. Psychiatry Investig 2020; 17(1): 2-8.
[http://dx.doi.org/10.30773/pi.2019.08.09] [PMID: 31587531]

Rights & Permissions Print Cite
Article Metrics
34
2
© 2024 Bentham Science Publishers | Privacy Policy